Polaroid Therapeutics
Polaroid Therapeutics is a Swiss-based biotech start-up, established in 2022 and incubated by the iconic Polaroid brand. The company is dedicated to addressing major challenges in antimicrobial therapies through cutting-edge technology and research. Its mission is to create a more human, meaningful, and healthier world by developing proprietary antimicrobial polymer technologies that reduce bioburden, improve patient outcomes, and do not trigger antimicrobial resistance (AMR). Polaroid Therapeutics focuses on advanced wound care, medical device coatings, and holistic therapeutic applications, aiming to set new standards in patient-centric care and global health.
Industries
N/A
Nr. of Employees
small (1-50)
Patents
Products
Antimicrobial polymer technology platform for wound care and device coatings
A polymer-based antimicrobial platform designed to be incorporated into wound dressings and device coatings to reduce bacterial bioburden with sustained activity while avoiding induction of antimicrobial resistance.
Prototype advanced wound dressings (CMC gelling fibre prototypes)
Prototype dressings combining antimicrobial polymers with carboxymethyl cellulose gelling fibres designed for cavity and complex wound management.
Antimicrobial polymer technology platform for wound care and device coatings
A polymer-based antimicrobial platform designed to be incorporated into wound dressings and device coatings to reduce bacterial bioburden with sustained activity while avoiding induction of antimicrobial resistance.
Prototype advanced wound dressings (CMC gelling fibre prototypes)
Prototype dressings combining antimicrobial polymers with carboxymethyl cellulose gelling fibres designed for cavity and complex wound management.
Services
Co-development projects with fibre manufacturers to integrate antimicrobial polymers into gelling-fibre dressings and run feasibility trials and prototyping.
Use of multimodal, multiscale AI to simulate clinical trials on digital twins and produce predictive insights to inform study design and risk mitigation.
Consortium-based translational research activities including co-funding and use of refurbished clinical facilities to enable early-stage wound treatment studies.
Co-development projects with fibre manufacturers to integrate antimicrobial polymers into gelling-fibre dressings and run feasibility trials and prototyping.
Use of multimodal, multiscale AI to simulate clinical trials on digital twins and produce predictive insights to inform study design and risk mitigation.
Consortium-based translational research activities including co-funding and use of refurbished clinical facilities to enable early-stage wound treatment studies.
Expertise Areas
- Antimicrobial polymer development
- Advanced wound care product development
- Medical device coating technologies
- Preclinical and translational research
Key Technologies
- Quaternized cationic antimicrobial polymers
- Carboxymethyl cellulose (CMC) gelling fibres
- Device surface antimicrobial coatings
- 3D printing for medical devices/dressings
News & Updates
Polaroid Therapeutics and The University of Hull have partnered to launch the world’s first £48M international Wound Innovation Centre (WIC), bringing together multidisciplinary experts to address critical issues in wound care and antimicrobial resistance.
Polaroid Therapeutics and SFM Limited are collaborating to develop a novel wound dressing that prevents infection and aids healing, leveraging proprietary antimicrobial polymer technology and advanced fibre technology.
Polaroid Therapeutics partners with Ingenix.AI to embed multimodal and multiscale agentic AI into clinical workflows, aiming to accelerate advanced patient-centred therapies and improve clinical trial outcomes.
Professor Sebastian Probst, a global authority in wound care, joins as Clinical Specialist Advisor to guide product development and improve patient outcomes.
Markus Rothmaier, with over two decades of pharmaceutical R&D leadership, joins as Head of Research and Development to drive product development and strategic partnerships.
CEO Ran Frenkel discusses the company's vision to redefine healing, focusing on prevention, patient empowerment, and open-source collaboration to combat antimicrobial resistance and improve chronic wound care.
Polaroid Therapeutics and The University of Hull have partnered to launch the world’s first £48M international Wound Innovation Centre (WIC), bringing together multidisciplinary experts to address critical issues in wound care and antimicrobial resistance.
Polaroid Therapeutics and SFM Limited are collaborating to develop a novel wound dressing that prevents infection and aids healing, leveraging proprietary antimicrobial polymer technology and advanced fibre technology.
Polaroid Therapeutics partners with Ingenix.AI to embed multimodal and multiscale agentic AI into clinical workflows, aiming to accelerate advanced patient-centred therapies and improve clinical trial outcomes.
Professor Sebastian Probst, a global authority in wound care, joins as Clinical Specialist Advisor to guide product development and improve patient outcomes.
Markus Rothmaier, with over two decades of pharmaceutical R&D leadership, joins as Head of Research and Development to drive product development and strategic partnerships.
CEO Ran Frenkel discusses the company's vision to redefine healing, focusing on prevention, patient empowerment, and open-source collaboration to combat antimicrobial resistance and improve chronic wound care.